Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Outset Medical, Inc.'s SEC filings document operating results, product and service revenue, gross margin, cash resources, and guidance for its dialysis technology business. Recent Form 8-K reports furnish earnings releases for the Tablo Hemodialysis System business and disclose material events such as FDA 510(k) clearance for the next-generation Tablo platform.
Proxy materials and current reports also cover governance and compensation matters, including board composition, director independence, committee appointments, executive compensation tables, pay-versus-performance disclosures, and equity awards. The filing record ties these disclosures to Outset’s capital structure, Nasdaq-listed common stock, and medical-device regulatory environment.
Outset Medical, Inc. director and Chair and CEO Leslie Trigg reported an open-market sale of 3,445 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required sale to cover tax withholding obligations tied to the vesting of 9,319 RSU-based shares and did not represent a discretionary trade.
After the sale, Trigg held 98,874 Common Stock shares directly, along with 584 shares held indirectly through the Trigg Family Trust and 41,666 shares held indirectly through the Trigg 2002 Rev Trust, all as of May 15, 2026.
Outset Medical, Inc. executive vice president Marc Nash reported an open-market sale of 1,582 shares of common stock at $3.70 per share. According to the footnote, this was a required “sell to cover” transaction to pay tax withholding on the vesting of 4,277 RSU shares and was not a discretionary trade. After the sale, Nash directly holds 38,393 shares of Outset Medical common stock.
Outset Medical, Inc. General Counsel John L. Brottem reported an open-market sale of 2,638 shares of Common Stock at $3.70 per share. According to the footnotes, this was a required "sell to cover" transaction to satisfy tax withholding obligations tied to the vesting of 5,033 RSU-based shares and is not a discretionary trade. After this tax-related sale, Brottem directly holds 30,277 shares of Common Stock. A separate footnote notes a correction to a previously reported 2,842-share tax-related sale, revising it to 2,862 shares due to an administrative error.
Outset Medical, Inc. ownership disclosure: BML Investment Partners, L.P. reports beneficial ownership of 2,519,706 shares of common stock, representing 13.6% of the class. The filing states shared voting and dispositive power of 2,519,701 shares and names Braden M. Leonard as indirect owner via BML Capital Management, LLC.
Outset Medical, Inc. disclosed that investment entity BML Investment Partners, L.P., associated with major holder Leonard Braden Michael, acquired 323,000 shares of common stock at $5.00 per share. The shares were assigned upon expiration of short June 2026 put options held by the reporting owner.
Following this option assignment, BML Investment Partners, L.P. indirectly holds 2,519,701 shares of Outset Medical common stock. Mr. Leonard, as managing member of BML Capital Management, LLC, exercises voting and investment control over the fund’s holdings but disclaims beneficial ownership except to the extent of his pecuniary interest.
OM reported a Section 144 notice describing restricted stock units that vested and were settled into 5,033 shares on 05/15/2026. The filing also shows a prior sale of 2,862 shares on 02/17/2026 attributed to John Brottem. The transaction is listed as equity compensation for services rendered.
OM reported a Form 144 disclosure showing a settlement of 4,277 vested Restricted Stock Units into Common Stock on 05/15/2026. The filing also records 1,830 shares of Common Stock sold on 02/17/2026 by Marc Nash within the prior three months.
OM submitted a Form 144 notice reporting 9,319 shares of Common Stock tied to the settlement of vested restricted stock units scheduled on 05/15/2026. The filing also records a prior sale of 3,384 shares on 02/17/2026 by Leslie Trigg. The transaction is described as equity compensation for services rendered.
Outset Medical, Inc. amendment to a Schedule 13G/A reports that Alyeska Investment Group, L.P., Alyeska Fund GP, LLC and Anand Parekh beneficially own 0 shares of Common Stock, representing 0.00% of the class as of 03/31/2026.
The filing is a joint statement under Rule 13d-1(k) signed by each party and certified by Jason Bragg, Chief Financial Officer, and Anand Parekh on 05/15/2026.
Outset Medical, Inc. disclosure amendment: Woodline Partners reports beneficial ownership of 292,437 shares of Outset Medical common stock, representing 1.6% based on 18,311,626 shares outstanding as of February 10, 2026. The shares are held directly by Woodline Master Fund LP and Woodline reports sole voting and dispositive power over 292,437 shares.
The filing is an amendment to a prior Schedule 13G and cites the Company’s Annual Report for the outstanding share count as of February 10, 2026.